Candel Therapeutics (CADL) Net Cash Flow (2020 - 2025)

Candel Therapeutics has disclosed Net Cash Flow across 6 years of filings, most recently posting $32.9 million for Q4 2025.

• Net Cash Flow for Q4 2025 came in at $32.9 million, down 61.77% year-over-year; the trailing twelve-month figure through Dec 2025 was $17.2 million (down 74.38% YoY), and the FY2025 annual result was $17.2 million, down 74.38% from the prior year.
• Net Cash Flow came in at $32.9 million for Q4 2025 at Candel Therapeutics, up from -$13.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $86.1 million in Q4 2024 to a low of -$13.7 million in Q3 2025.
• The 5-year median for Net Cash Flow is -$6.4 million (2021), against an average of $4.2 million.
• Across the five-year window, Net Cash Flow surged 2964.06% in 2021 and sank 192.37% in 2023, its largest moves.
• Candel Therapeutics' Net Cash Flow stood at -$5.7 million in 2021, then declined by 24.09% to -$7.1 million in 2022, then decreased by 6.25% to -$7.6 million in 2023, then soared by 1237.33% to $86.1 million in 2024, then slumped by 61.77% to $32.9 million in 2025.
• The last three Net Cash Flow figures came in at $32.9 million (Q4 2025), -$13.7 million (Q3 2025), and $8.5 million (Q2 2025), per Business Quant data.